<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article36</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/BRIDGE" style="display:block; margin-bottom:10px;">BRIDGE Original</a></li>
<h2><strong>BRIDGE</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Bridging Anticoagulation in Patients with Atrial Fibrillation".The New England Journal of Medicine. 2015. 373(9):823-833.PubMed•Full text•PDF<br/>
<br/>
<h2><strong>Contents</strong></h2><br/>
<br/>
1 Clinical Question<br/>
2 Bottom Line<br/>
3 Major Points<br/>
4 Guidelines<br/>
5 Design<br/>
6 Population<br/>
  6.1 Inclusion Criteria<br/>
  6.2 Exclusion Criteria<br/>
  6.3 Baseline Characteristics<br/>
7 Interventions<br/>
8 Outcomes<br/>
  8.1 Primary Outcomes<br/>
  8.2 Secondary Outcomes<br/>
9 Criticisms<br/>
10 Funding<br/>
11 Further Reading<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
<br/>
In patients with atrial fibrillation who require a temporary interruption of warfarin for an elective operation or other elective invasive procedure, is forgoing bridging anticoagulation with low-molecular-weight heparin noninferior to perioperative bridging for the prevention of arterial thromboembolism and does it decrease the risk of major bleeding?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
<br/>
For patients with atrial fibrillation who require a temporary interruption of warfarin for an elective procedure, a strategy of forgoing bridging anticoagulation was noninferior to perioperative bridging with low-molecular-weight heparin for preventing arterial thromboembolism and reduced the risk of major bleeding.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/>
<br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
<br/>
As of the last knowledge update, no guidelines have been published that reflect the results of this trial.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
<br/>
- Randomized, double-blind, placebo-controlled trial<br/>
- N=1,884<br/>
- No-bridging group (placebo) (n=950)<br/>
- Bridging group (dalteparin) (n=934)<br/>
- Setting: 108 centers in the United States and Canada<br/>
- Enrollment: 2009-2014<br/>
- Mean follow-up: 30 days after the procedure<br/>
- Analysis: Intention-to-treat<br/>
- Primary outcomes: Arterial thromboembolism and major bleeding within 30 days after the procedure<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
<br/>
Inclusion Criteria<br/>
<br/>
- Age ≥18 years <br/>
- Chronic atrial fibrillation or flutter, confirmed by previous electrocardiography or pacemaker interrogation<br/>
- Receiving warfarin therapy for ≥3 months with an INR therapeutic range of 2.0 to 3.0<br/>
- Undergoing an elective operation or other invasive procedure requiring warfarin interruption <br/>
- At least one CHADS2 stroke risk factor<br/>
<br/>
Exclusion Criteria<br/>
<br/>
- Mechanical heart valve<br/>
- Stroke, systemic embolism, or transient ischemic attack within the previous 12 weeks<br/>
- Major bleeding within the previous 6 weeks<br/>
- Creatinine clearance &lt;30 ml/min<br/>
- Platelet count &lt;100×103/mm³<br/>
- Planned cardiac, intracranial, or intraspinal surgery<br/>
<br/>
Baseline Characteristics<br/>
<br/>
- Mean age: 71.7 years<br/>
- Male: 73.4%<br/>
- Mean body weight: 95.8 kg<br/>
- Mean CHADS2 score: 2.3<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
<br/>
- Discontinuation of warfarin 5 days before the procedure<br/>
- Randomization to placebo (no-bridging) or bridging treatment with dalteparin (100 IU/kg subcutaneously twice daily) starting 3 days before the procedure until 24 hours before the procedure and then for 5 to 10 days after the procedure<br/>
- Resumption of warfarin within 24 hours after the procedure<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
<br/>
Primary Outcomes<br/>
<br/>
- Arterial thromboembolism: 0.4% in the no-bridging group vs. 0.3% in the bridging group (risk difference, 0.1 percentage points; 95% CI, −0.6 to 0.8; P=0.01 for noninferiority; P=0.73 for superiority)<br/>
- Major bleeding: 1.3% in the no-bridging group vs. 3.2% in the bridging group (relative risk, 0.41; 95% CI, 0.20 to 0.78; P=0.005 for superiority)<br/>
<br/>
Secondary Outcomes<br/>
<br/>
- Acute myocardial infarction, deep-vein thrombosis, pulmonary embolism, or death: no significant difference between the two groups<br/>
- Minor bleeding: significantly lower in no-bridging group (12.0% vs. 20.9%, P&lt;0.001)<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
<br/>
- The trial did not include patients with mechanical heart valves, and few patients had high CHADS2 scores.<br/>
- The trial did not include procedures with high rates of arterial thromboembolism and bleeding, such as major surgery.<br/>
- The observed rate of arterial thromboembolism was lower than expected, potentially affecting the power to detect a clear benefit of bridging.<br/>
- The trial was conducted during the period where the use of warfarin is being overtaken by newer direct oral anticoagulants.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
<br/>
Supported by grants from the National Heart, Lung, and Blood Institute for the clinical coordinating center and for the data coordinating center. Dalteparin supplied by Eisai through an unrestricted investigator-initiated grant.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
<br/>
Please refer to the original publication for a complete list of references and further reading.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
